Track topics on Twitter Track topics that are important to you
DelveInsight's, Vasculitis Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Vasculitis. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Vasculitis. This report provides information on the therapeutic development for Vasculitis, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
AnGes MG Inc.
Coherus BioSciences Inc.
F. HoffmannLa Roche Ltd.
KStemcell Co. Ltd.
Panacea Biotec Limited
Sandoz International GmbH
Teijin Pharma Limited
Vasculitis Pipeline Drugs
Vasculitis Pipeline Assessment
Vasculitis Pipeline Analysis
Vasculitis Drugs under Development
Vasculitis Discovery drugs
Vasculitis Preclinical drugs
Vasculitis Phase I drugs
Vasculitis Phase II drugs
Vasculitis Phase III Pipeline Drugs Assessment
Vasculitis Preregistration drugs
Vasculitis Molecules in pipeline
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...